Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

Synchronization of the vegetative cycle and SP formation in <i>Eudorina.</i> by Hiroko Kawai-Toyooka (382362)

Subjects:

Time course of CM-induced SP formation efficiency during colony development of <i>Eudorina.</i> by Hiroko Kawai-Toyooka (382362)

Subjects:

ActAs and CoT prompt strategies do not result in decreased error rate for tasks with increasing complexity. by Jacqueline A. Jansen (14894276)

Self-correction prompt strategy results in decreased error rate for all tasks with increasing complexity. by Jacqueline A. Jansen (14894276)

fileCont prompt strategy results in decreased error rate for some tasks with increasing complexity. by Jacqueline A. Jansen (14894276)

The data underlying the graphs shown in Figs 3–6 (main text) and S1 Fig and S3 Fig (Supporting Information). by Hiroko Kawai-Toyooka (382362)

Subjects:

GPT-4 results in decreased error rate for all tasks with increasing complexity when compared to GPT-3.5-turbo. by Jacqueline A. Jansen (14894276)

The number of COVID-19 patients admitted to the health system during the pandemic with the timing of data collection for the 2 study phases. by Elie Mulhem (22537863)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Evolutionary transitions of gamete dimorphism and gametogenesis induction cues in volvocine algae. by Hiroko Kawai-Toyooka (382362)

Subjects:

Effect of CM dilution and nitrogen availability on male CM-induced SP formation. by Hiroko Kawai-Toyooka (382362)

Subjects:

Effect of pronase pretreatment of male CM on SP formation. by Hiroko Kawai-Toyooka (382362)

Subjects:

SP-forming activity of CM precipitated by 80% saturated ammonium sulfate. by Hiroko Kawai-Toyooka (382362)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects: